Contrast-enhanced Ultrasonography Guidance Avoids US-CT/MR Fusion Error for Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma

Overview

Journal BMC Med Imaging

Publisher Biomed Central

Specialty Radiology

Date 2024 Nov 28

PMID 39609743

Authors

Yang-Bor Lu

Yung-Ning Huang

Yu-Chieh Weng

Tung-Ying Chiang

Ta-Kai Fang

Wei-Ting Chen

Jung-Chieh Lee

Affiliations

Soon will be listed here.

Abstract

Background: This study evaluated the impact of contrast-enhanced ultrasonography (CEUS) combined with CT or MRI fusion imaging on percutaneous radiofrequency ablation (RFA) outcomes for hepatocellular carcinoma (HCC) inconspicuous on conventional ultrasonography (US).

Methods: Patients were categorized into US-inconspicuous (USI) and US-conspicuous (USC) groups based on US imaging. The parameters of viable HCCs ⎯ including diameter, location, and RFA efficacy ⎯ were compared between USI and USC groups. Moreover, the breathing fusion imaging errors were measured. The differences in technical success, technical efficacy, local tumor progression, new tumor occurrence, and overall survival rate between USI and USC groups were analyzed.

Results: Sixty-five patients with 106 lesions were included. CEUS showed high consistency with CT/MRI but revealed larger diameters (p < 0.001) and more feeding arteries (p = 0.019) than CT/MRI. Breathing fusion imaging errors averaged 17 ± 4 mm, significantly affecting lesions in segments II, III, V, and VI (p < 0.001). The USI group had more lesions ablated per patient in a single RFA procedure (p = 0.001) than the USC group. No significant differences were observed in technical success rate, technical efficacy rate, local tumor progression rate, and overall survival rate between the two groups.

Conclusions: CEUS combined with fusion imaging provides detailed information on viable HCCs and their feeding arteries. CEUS-guided RFA avoids fusion imaging errors and achieves comparable efficacy in both US-conspicuous and US-inconspicuous HCCs.

References

Lee J, Yan K, Lee S, Yang W, Chen M . Focal Liver Lesions: Real-time 3-Dimensional Contrast-Enhanced Ultrasonography Compared With 2-Dimensional Contrast-Enhanced Ultrasonography and Magnetic Resonance Imaging. J Ultrasound Med. 2017; 36(10):2015-2026. DOI: 10.1002/jum.14268. View

Xie D, Ren Z, Zhou J, Fan J, Gao Q . 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020; 9(4):452-463. PMC: 7423548. DOI: 10.21037/hbsn-20-480. View

Shao Y, Wang S, Lin S . Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2020; 120(4):1051-1060. DOI: 10.1016/j.jfma.2020.10.031. View

Zhang Z, Lee J, Yang W, Yan K, Wu W, Wang Y . Percutaneous ablation of the tumor feeding artery for hypervascular hepatocellular carcinoma before tumor ablation. Int J Hyperthermia. 2018; 35(1):133-139. DOI: 10.1080/02656736.2018.1484525. View

Lee C, Chen W, Lin C, Teng W, Lin S, Chiu C . Radiofrequency ablation assisted by real-time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high-risk locations. Kaohsiung J Med Sci. 2015; 31(8):413-9. DOI: 10.1016/j.kjms.2015.06.002. View

Esfahani S, Zhai X, Chen M, Amira A, Bensaali F, AbiNahed J . Lattice-Boltzmann interactive blood flow simulation pipeline. Int J Comput Assist Radiol Surg. 2020; 15(4):629-639. DOI: 10.1007/s11548-020-02120-3. View

Wen N, Cai Y, Li F, Ye H, Tang W, Song P . The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022; 16(1):20-30. DOI: 10.5582/bst.2022.01061. View

Lee M . Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography. 2014; 33(4):227-39. PMC: 4176112. DOI: 10.14366/usg.14021. View

Yang W, Yan K, Wu G, Wu W, Fu Y, Lee J . Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes. World J Gastroenterol. 2015; 21(5):1554-66. PMC: 4316097. DOI: 10.3748/wjg.v21.i5.1554. View

10.

Lee M, Lim H, Rhim H, Cha D, Kang T, Song K . Percutaneous Radiofrequency Ablation of Small (1-2 cm) Hepatocellular Carcinomas Inconspicuous on B-Mode Ultrasonographic Imaging: Usefulness of Combined Fusion Imaging with MRI and Contrast-Enhanced Ultrasonography. Can J Gastroenterol Hepatol. 2018; 2018:7926923. PMC: 6022314. DOI: 10.1155/2018/7926923. View

11.

Ansari M, Yang Y, Meher P, Dakua S . Dense-PSP-UNet: A neural network for fast inference liver ultrasound segmentation. Comput Biol Med. 2023; 153:106478. DOI: 10.1016/j.compbiomed.2022.106478. View

12.

Ansari M, Yang Y, Balakrishnan S, AbiNahed J, Al-Ansari A, Warfa M . A lightweight neural network with multiscale feature enhancement for liver CT segmentation. Sci Rep. 2022; 12(1):14153. PMC: 9391485. DOI: 10.1038/s41598-022-16828-6. View

13.

Chen M, Yang W, Yan K, Dai Y, Wu W, Fan Z . The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation. Clin Radiol. 2007; 62(8):752-60. DOI: 10.1016/j.crad.2006.12.013. View

14.

Toshikuni N, Tsutsumi M, Takuma Y, Arisawa T . Real-time image fusion for successful percutaneous radiofrequency ablation of hepatocellular carcinoma. J Ultrasound Med. 2014; 33(11):2005-10. DOI: 10.7863/ultra.33.11.2005. View

15.

Hakime A, Deschamps F, De Carvalho E, Teriitehau C, Auperin A, De Baere T . Clinical evaluation of spatial accuracy of a fusion imaging technique combining previously acquired computed tomography and real-time ultrasound for imaging of liver metastases. Cardiovasc Intervent Radiol. 2010; 34(2):338-44. DOI: 10.1007/s00270-010-9979-7. View

16.

Lee M, Rhim H, Cha D, Kim Y, Choi D, Kim Y . Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol. 2012; 198(6):1438-44. DOI: 10.2214/AJR.11.7568. View

17.

Ahmed M, Solbiati L, Brace C, Breen D, Callstrom M, Charboneau J . Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014; 273(1):241-60. PMC: 4263618. DOI: 10.1148/radiol.14132958. View

18.

Dietrich C, Nolsoe C, Barr R, Berzigotti A, Burns P, Cantisani V . Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med. 2020; 41(5):562-585. DOI: 10.1055/a-1177-0530. View

19.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

20.

Chen M, Yang W, Yan K, Zou M, Solbiati L, Liu J . Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients--mathematic model, overlapping mode, and electrode placement process. Radiology. 2004; 232(1):260-71. DOI: 10.1148/radiol.2321030821. View